Structure Therapeutics (NASDAQ:GPCR) Upgraded at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Structure Therapeutics (NASDAQ:GPCR) to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports.

A number of other analysts have also weighed in on the stock. Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 11th. BMO Capital Markets reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, January 6th. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. Finally, Stifel Nicolaus upped their price objective on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.45.

Structure Therapeutics Trading Down 1.2%

NASDAQ:GPCR traded down $1.13 during midday trading on Tuesday, hitting $90.75. 283,097 shares of the company traded hands, compared to its average volume of 1,350,785. The firm has a market capitalization of $5.51 billion, a P/E ratio of -74.31 and a beta of -2.05. The firm’s fifty day moving average is $59.82 and its 200-day moving average is $36.02. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). On average, research analysts expect that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GPCR. State of Wyoming purchased a new stake in shares of Structure Therapeutics in the 2nd quarter worth approximately $28,000. EverSource Wealth Advisors LLC raised its stake in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after buying an additional 901 shares in the last quarter. Assetmark Inc. lifted its holdings in Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after buying an additional 820 shares during the period. PNC Financial Services Group Inc. boosted its position in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after acquiring an additional 994 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd boosted its position in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after acquiring an additional 1,146 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.